STERIS to Report Q2 Earnings: Here's What to Expect

Core Insights - STERIS plc (STE) is set to announce its second-quarter fiscal 2026 results on November 6, with expectations of revenue and EPS growth [1][10] - The company reported adjusted EPS of $2.34 in the last quarter, exceeding the Zacks Consensus Estimate by 0.86% [1] - STE has consistently beaten earnings estimates in three of the last four quarters, with an average surprise of 2.02% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for revenues is $1.43 billion, reflecting a 7.4% increase year-over-year [2] - The EPS estimate stands at $2.38, indicating an 11.2% year-over-year growth [2] Segment Performance Expectations - Healthcare segment is expected to show robust growth, with a projected revenue increase of 5.9% year-over-year [5] - The Applied Sterilization Technologies (AST) segment is anticipated to see a 10.8% year-over-year revenue growth, driven by stable global MedTech customers and increased bioprocessing demand [6][7] - Life Sciences segment is projected to grow by 7.2% year-over-year, benefiting from strong consumables and services revenue [8] Earnings Surprise Potential - STERIS has an Earnings ESP of 0.00%, indicating a lower likelihood of beating earnings estimates this quarter [11] - The company currently holds a Zacks Rank of 4 (Sell), suggesting caution in investment decisions [11]